• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $UPXI

    Upexi Inc.

    Subscribe to $UPXI
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    IPO Year: 2021

    Exchange: NASDAQ

    Recent Analyst Ratings for Upexi Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Upexi Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      5/31/23 7:05:10 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:37:37 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

      SC 13G/A - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:36:56 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

      SC 13G/A - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:36:22 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    Upexi Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:26 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Salkind Gene bought $550,002 worth of shares (241,229 units at $2.28), increasing direct ownership by 195% to 365,127 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:17 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Marshall Allan bought $44,739 worth of shares (77,773 units at $0.58), increasing direct ownership by 3% to 2,939,654 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      3/18/24 4:55:17 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Marshall Allan bought $72,109 worth of shares (103,013 units at $0.70), increasing direct ownership by 4% to 2,861,881 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      3/6/24 3:04:50 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Marshall Allan bought $12,340 worth of shares (12,916 units at $0.96), increasing direct ownership by 0.47% to 2,767,249 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      12/20/23 1:37:18 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Marshall Allan bought $84,952 worth of shares (90,001 units at $0.94), increasing direct ownership by 3% to 2,754,333 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      12/7/23 2:42:38 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Marshall Allan bought $40,652 worth of shares (53,474 units at $0.76), increasing direct ownership by 2% to 2,664,332 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      12/6/23 2:47:14 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    Upexi Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Williams Thomas Charles

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:45 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:26 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Salkind Gene bought $550,002 worth of shares (241,229 units at $2.28), increasing direct ownership by 195% to 365,127 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:17 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Dugan Lawrence

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:08 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Marshall Allan bought $44,739 worth of shares (77,773 units at $0.58), increasing direct ownership by 3% to 2,939,654 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      3/18/24 4:55:17 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Marshall Allan bought $72,109 worth of shares (103,013 units at $0.70), increasing direct ownership by 4% to 2,861,881 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      3/6/24 3:04:50 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Marshall Allan bought $12,340 worth of shares (12,916 units at $0.96), increasing direct ownership by 0.47% to 2,767,249 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      12/20/23 1:37:18 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Marshall Allan bought $84,952 worth of shares (90,001 units at $0.94), increasing direct ownership by 3% to 2,754,333 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      12/7/23 2:42:38 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Marshall Allan bought $40,652 worth of shares (53,474 units at $0.76), increasing direct ownership by 2% to 2,664,332 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      12/6/23 2:47:14 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    Upexi Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BitGo and Upexi Announce Strategic Partnership to Secure Digital Asset Treasury Holdings

      BitGo, the leading infrastructure provider of digital asset solutions, today announced a strategic partnership with Upexi Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space. Under this partnership, Upexi will leverage BitGo's secure custodial and over-the-counter (OTC) trading services to manage its growing digital asset portfolio. This move builds on Upexi's recent announcement that it has increased its Solana (SOL) treasury holdings to over 595,000 tokens, valued at approximately $100 million at current value, and has begun generating staking revenue as part of its broad

      5/13/25 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Regains Compliance with NASDAQ

      Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

      12/23/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split

      DALLAS, TX, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced that it has launched an investigation into potential stock manipulation related to and following its recent reverse stock split, which was effective as of October 16, 2024. This decision follows a comprehensive review of highly irregular trading patterns and an unprecedented increase in the number of shareholder accounts, factors that collectively raise concerns about potential stock manipulation. This investigation also follows a recent r

      12/4/24 7:00:00 AM ET
      $MGRX
      $UPXI
      Misc Health and Biotechnology Services
      Health Care
      Medicinal Chemicals and Botanical Products
    • Upexi Files litigation in Nevada as first Step in Determining Manipulation of Fractional Share Roundups during Reverse Stock Split

      TAMPA, FL / ACCESSWIRE / November 25, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, announces the Company has filed a complaint in the United States District Court for the District of Nevada to pursue the groups and individuals who orchestrated the manipulative and fraudulent activity in the shares round-up scheme related to Upexi's reverse stock split. Upexi anticipates that the court, through the discovery process, will enable the Company to determine who are the individuals owning the accounts and engaged in the manipulative trading transactions within those accounts in connection with a

      11/25/24 8:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Recieves Notice from The Nasdaq Stock Market

      TAMPA, FL / ACCESSWIRE / November 22, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer ("DTC") brand owner and innovator in aggregation, received a Non Compliance Letter from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to timely file its Form 10-Q Quarterly Report for the period ended September 30, 2024, in violation of Nasdaq Listing Rule 5250(c)(1).The Company failed to timely file due to circumstances beyond its control, and intends to file its Form 10-Q Quarterly Report shortly after it is able to file its Form 10-K Annual Report.Pursuant to the Nasdaq Listing Rules, the Company has until December 20, 2024

      11/22/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to Take Action Against Apparent Stock Manipulation of Fractional Share Roundup with Reverse Stock Split

      TAMPA, FL / ACCESSWIRE / October 25, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, announces an issue affecting the Company's shareholders in regard to the recently completed reverse stock split.Prior to the Company's required announcement regarding the reverse stock split on September 27,2024, Upexi estimates there were less than 5,000 shareholders of record. Post-split 5 Brokerage firms have requested roundup shares equaling approximately 199,059 shares of the Company's common stock out of a total of 202,183 round up shares of the Company's common stock requested.The 202,183 roundup share

      10/25/24 8:30:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to File Form 10-K on November 1st and Regains Compliance with Nasdaq Minimum Bid Price Rule

      TAMPA, FL / ACCESSWIRE / October 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer ("DTC") brand owner and innovator in aggregation, received a Non Compliance Letter from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to timely file its Form 10-K Annual Report for the period ended June 30, 2024, in violation of Nasdaq Listing Rule 5250(c)(1). The Company failed to timely file due to circumstances beyond its control, and intends to file its Form 10-K Annual Report on or before Friday, November 1, 2024.In addition, on October 17, 2024, the Company received written notice (the "Compliance Notice") from Nasdaq info

      10/23/24 8:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Provides Shareholder Update on Restructuring to Reduce Debt and Increase Working Capital

      TAMPA, FL / ACCESSWIRE / August 5, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer ("DTC") brand owner and innovator in aggregation, today is providing shareholders with an update on its restructuring to reduce debt and increase working capital through the sale of assets.After the closing of several transactions since the nine month period ended, March 31, 2024, the Company has:$16.1 million eliminated in debt and accrued interest$7.4 million in cash to strengthen the balance sheetApproximately $1.5 million eliminated in excess operational costs, without affecting operationsAllan Marshall, CEO of Upexi, commented, "The Upexi manageme

      8/5/24 8:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Reports Fiscal Third Quarter 2024 Financial Results

      TAMPA, FL / ACCESSWIRE / July 9, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer ("DTC") brand owner and innovator in aggregation, today reported its financial results for the fiscal third quarter 2024 ending March 31, 2024.Allan Marshall, CEO of Upexi, commented, "Our year-over-year quarterly financial results include management's decision to discontinue sales of certain products. Subsequent to the quarter, we made continued progress on our restructuring, which is estimated to provide us with sufficient working capital to fund our operations while reducing our debt to a minimal level. We anticipate the restructuring efforts to resul

      7/9/24 8:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to File Form 10-Q on July 8th

      TAMPA, FL / ACCESSWIRE / July 1, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer ("DTC") brand owner and innovator in aggregation, intends to file its form 10-Q for the period ended March 31, 2024 on Monday, July 8, 2024. The Company is not able to file this week due to its auditor's office closure during the first week of July.About Upexi, Inc.:Upexi is a multi-faceted brand owner with established brands in the health, wellness, pet, beauty, and other growing markets. We operate in emerging industries with high growth trends and look to drive organic growth of our current brands. We focus on direct to consumer and Amazon brands that

      7/1/24 4:05:00 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    Upexi Inc. Financials

    Live finance-specific insights

    See more
    • Upexi Regains Compliance with NASDAQ

      Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

      12/23/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Reports Fiscal Second Quarter 2024 Financial Results

      TAMPA, FL / ACCESSWIRE / February 14, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today reported its financial results for the fiscal second quarter 2024 ending December 31, 2023."During the quarter we continued to focus on optimizing and streamlining our operations, investing in our higher margin Brand Products and generating positive Adjusted EBITDA. While revenue for the most recent fiscal second quarter decreased sequentially, the operating measures we took allowed us to increase gross profit margins to 38%, as compared to the prior fiscal first quarter of 31.8%. We also generated pos

      2/14/24 4:05:00 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to Host Fiscal 2024 Second Quarter Financial Results Conference Call on February 14th at 4:30 PM ET

      TAMPA, FL / ACCESSWIRE / February 12, 2024 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Wednesday, February 14, 2024 at 4:30 p.m. ET, to discuss its financial results for the fiscal 2024 second quarter and provide a business update.Financial Results Conference CallEvent:Fiscal 2024 Second Quarter Financial Results Conference CallDate:Wednesday, February 14, 2024Time:4:30 p.m. Eastern TimeLive Call:1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)Webcast:https://ir.upexi.com/news-events/ir-calendarFor those unable to join the confe

      2/12/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Revenue Increases 144% Year-Over-Year and 53.5% Sequentially to $27.3 Million for Fiscal First Quarter 2024

      TAMPA, FL / ACCESSWIRE / November 20, 2023 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today announced its financial results for the fiscal first quarter 2024 ending September 30, 2023."Revenue for our fiscal first quarter 2024 grew 144% year-over-year and 53.5% sequentially driven by growth in both branded products and re-commerce," commented CEO of Upexi, Allan Marshall. "While our cost cutting measures are now beginning to yield material year-over-year decreases in operating expenses as a percentage of revenue, we have also continued to invest significantly in the future growth of our brand

      11/20/23 4:05:00 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Preannounces Revenue of $27.3 Million for Fiscal 2024 First Quarter and Reschedules Financial Results Conference Call for November 20th at 4:30 PM ET

      TAMPA, FL / ACCESSWIRE / November 14, 2023 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced preliminary and unaudited financial results for the fiscal 2024 first quarter ended September 30, 2023.Based on a preliminary and unaudited review, the Company anticipates:Revenue of approximately $27.3 million, an increase of 136% year-over-year and 53.2% sequentially, and above the previously issue revenue guidance range of $26 million to $27 million.Adjusted EBITDA of approximately $700,000 as compared to an Adjusted EBITDA loss of approximately $525,000, approximately a $1.2 million improv

      11/14/23 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to Host Fiscal 2024 First Quarter Financial Results Conference Call on November 14th at 4:30 PM ET

      TAMPA, FL / ACCESSWIRE / November 3, 2023 / Upexi Inc. (NASDAQ:PXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Tuesday, November 14, 2023 at 4:30 p.m. ET, to discuss its financial results for the first quarter of fiscal 2024 and provide a business update.Financial Results Conference CallEvent:Fiscal 2024 First Quarter Financial Results Conference CallDate:Tuesday, November 14, 2023Time:4:30 p.m. Eastern TimeLive Call:1-877-300-8521 (U.S. Toll-Free) or 1-412-317-6026 (International)Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1641098&tp_key=e91f34a943For those una

      11/3/23 8:30:00 AM ET
      $PXI
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Fiscal 2023 Revenue Increases 250% Year-Over-Year to $80.7 Million and Provides Revenue Guidance Range for Fiscal 2023 First Quarter

      Management provides revenue guidance range for fiscal 2023 first quarter of $26 million to $27 millionTAMPA, FL / ACCESSWIRE / October 2, 2023 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today announced its financial results for the fiscal year ending June 30, 2023."Revenue growth year-over-year was predominately driven by the performance of our leading brands, VitaMetica, Lucky Tail and Tytan Tiles, as well as our re-commerce business. Even as we continue to integrate the operations of our acquisitions and reduced non-acquisition operating expenses by $1.9 million, we were able to report $1.2

      10/2/23 4:01:00 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to Host Fiscal 2023 Full Year Financial Results Conference Call on October 2nd at 4:30 PM ET

      CLEARWATER, FL / ACCESSWIRE / September 28, 2023 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Monday, October 2, 2023 at 4:30 p.m. ET, to discuss its financial results for the fiscal 2023 full year and provide a business update.Financial Results Conference CallEvent:Fiscal 2023 Full Year Financial Results Conference CallDate:Monday, October 2, 2023Time:4:30 p.m. Eastern TimeLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1634526&tp_key=7536fca2faFor those unable to jo

      9/28/23 4:15:00 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Provides Corporate Update

      CLEARWATER, FL / ACCESSWIRE / August 17, 2023 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today is providing shareholders with a corporate update and is increasing previously announced revenue guidance for full year 2023 to exceed $100 million. Management will be providing shareholders with a specific revenue guidance range during its fiscal 2023 financial results conference call in mid to late-September.Upexi CEO Allan Marshall stated, "We continue to execute and grow our business segments including Vitamedica, Tytan Tiles, and Lucky Tail. Management remains confident in its ability to exceed

      8/17/23 8:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to Host Fiscal 2023 Third Quarter Financial Results on May 15th at 4:30 PM ET

      CLEARWATER, FL / ACCESSWIRE / May 9, 2023 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Monday, May 15, 2023 at 4:30 p.m. ET to discuss its fiscal 2023 third quarter financial results and provide a business update.Financial Results Conference CallEvent:Fiscal 2023 Third Quarter Financial Results Conference CallDate:Monday, May 15, 2023Time:4:30 p.m. Eastern TimeLive Call:1-877-300-8521 (U.S. Toll-Free) or 1-412-317-6026 (International)Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1613123&tp_key=7d65f8a311For those unable to join the confere

      5/9/23 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    Upexi Inc. SEC Filings

    See more
    • Upexi Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      5/23/25 5:00:13 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-1 filed by Upexi Inc.

      S-1 - UPEXI, INC. (0001775194) (Filer)

      5/22/25 5:04:41 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      5/16/25 5:00:13 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Upexi Inc.

      10-Q - UPEXI, INC. (0001775194) (Filer)

      5/16/25 6:44:30 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      5/13/25 6:01:40 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Upexi Inc.

      DEF 14A - UPEXI, INC. (0001775194) (Filer)

      5/12/25 4:05:20 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      5/7/25 8:30:36 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SCHEDULE 13G filed by Upexi Inc.

      SCHEDULE 13G - UPEXI, INC. (0001775194) (Subject)

      5/1/25 7:59:04 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      4/30/25 9:15:26 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form PRE 14A filed by Upexi Inc.

      PRE 14A - UPEXI, INC. (0001775194) (Filer)

      4/29/25 5:00:09 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care